Mark Hollmer

  • Citations Per Year
Learn More
VOLUME 25 NUMBER 1 JANUARY 2007 NATURE BIOTECHNOLOGY and Novartis grew out of a settlement of that lawsuit in 1996. Seven years later, during which time Genentech virtually developed Xolair on its own in the US, the mAb received FDA marketing approval as an asthma therapy. By eliminating the royalty payment it has paid Tanox since then, and also gaining(More)
Next year, San Diego–based Ligand Pharmaceuticals is hoping to launch a thirdgeneration selective estrogen receptor modulator (SERM) that it developed with Wyeth of Collegeville, Pennsylvania. The company is among as many as two dozen around the world who believe they can hit a home run in the race to develop the next generation of SERM drugs. Most are(More)
  • 1